Braden Parker
Corporate Officer/Principal en ORCHARD THERAPEUTICS PLC .
Perfil
Braden Parker is currently the Chief Commercial Officer at Orchard Therapeutics Plc.
Previously, he worked as the Vice President & General Manager at PTC Therapeutics, Inc. He completed his undergraduate degree at the University of Notre Dame and holds an MBA from The Leonard N Stern School of Business.
Cargos activos de Braden Parker
| Empresas | Cargo | Inicio |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Braden Parker.
| Empresas | Cargo | Fin |
|---|---|---|
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formación de Braden Parker.
| The Leonard N Stern School of Business | Masters Business Admin |
| University of Notre Dame | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Braden Parker
